INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Announces That Janssen Has Initiated a Phase 2a Study to Evaluate the Combination of AL-335, Odalasvir (ACH-3102), and Simeprevir for the Treatment of Genotype 1 Chronic HCV
Once Daily Triple Direct-Acting Antiviral Regimen Will be Evaluated for Treatment Durations of Four, Six or Eight Weeks
View HTML
Toggle Summary Achillion to Present at the Credit Suisse 24th Annual Healthcare Conference
NEW HAVEN, Conn., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 24 th Annual Credit Suisse Healthcare Conference on Wednesday,
View HTML
Toggle Summary Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology Detailing Novel Results With Factor D Inhibitors
- Highly potent, specific, and oral factor D inhibitors effectively block hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) cells and mitigate the accumulation of C3 fragments   — - Inhibitory effect against atypical hemolytic uremic syndrome (aHUS) demonstrated by inhibitors in a recently
View HTML
Toggle Summary Achillion Reports Third Quarter And Nine Month 2015 Financial Results
NEW HAVEN, Conn., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2015. For the third quarter of 2015, Achillion reported a net income of $26.3 million or $0.19 per share, compared
View HTML
Toggle Summary Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) cells; mitigate the accumulation of C3 fragments; and its inhibitory effect against
View HTML
Toggle Summary Achillion Appoints Dr. Frank Verwiel to Board of Directors
NEW HAVEN, Conn., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of Frank Verwiel, M.D., former President and Chief Executive Officer of Aptalis Pharma, to Achillion's Board of Directors.
View HTML
Toggle Summary Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer
NEW HAVEN, Conn., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that Joel Barrish, Ph.D., has been named the Company's Chief Scientific Officer (CSO) and Executive Vice President, effective January 4, 2016.
View HTML
Toggle Summary Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
NEW HAVEN, Conn., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016.
View HTML
Toggle Summary Achillion to Present at the Leerink Partners 5th Annual Global Healthcare Conference
NEW HAVEN, Conn., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Leerink Partners 5 th Annual Global Healthcare Conference on
View HTML
Toggle Summary Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
Company's Proprietary Complement Platform Focuses on Advancing Factor D Inhibitor Drug Candidates That Could Treat Ultra-Rare Diseases Such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Other Complement-Mediated Diseases
View HTML